Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront
Get Quartz in your inbox
Free daily briefing on global business news.
Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront
Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324
Jeff Schear / Getty Images
Johnson & Johnson $JNJ agreed to acquire Ollin Biosciences, a clinical-stage drugmaker focused on treatments for serious eye diseases, in a deal worth $2.2 billion upfront, the company said on Monday.
The agreement also provides for as much as $1.125 billion in additional payments if certain........
